This article was originally published in The Gray Sheet
Licensing pact will allow Jomed to use Fujisawa Pharmaceutical's Prograf (tacrolimus) immunosuppressant drug on stents to help prevent restenosis. In November, Beringen, Switzerland-based Jomed inked an agreement with Alcove to use its proprietary nano-porous ceramic stent surface technology. Clinical trials of Jomed's drug eluting stent will commence by year-end...
You may also be interested in...
GSK creates another partnership centered on its vaccine adjuvant technology, this time with China's Xiamen Innovax.
Lab testing for COVID-19 has risen to a new high of 314,000 tests per week in Germany, where the concerns are perhaps less about test availability than staff numbers to oversee the testing protocols.
A new European Commission guidance document explains the regulatory basics and much- altered emergency market entry criteria for new entrants to devices sector amid the COVID-19 crisis.